Product image of Imuldosa (Ustekinumab) supplied by GNH India

Imuldosa

Active Ingredient:
Ustekinumab
Origin:
EU

Imuldosa (Ustekinumab)

Ustekinumab, the active ingredient in Imuldosa, is an interleukin‑12/23 inhibitor presented as a sterile solution for injection for intravenous administration. It is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease, providing targeted immunomodulation in adult patients who require systemic therapy.

GNH India supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets. Our distribution network includes procurement teams in Europe, Asia and the Americas, with dedicated cold‑chain logistics for biologic products.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ustekinumab is used to modulate the interleukin‑12/23 pathway in several immune‑mediated inflammatory disorders.

  • Plaque psoriasis: reduces skin lesions and systemic inflammation in adults with moderate to severe disease, improving quality of life.
  • Psoriatic arthritis: alleviates joint pain, swelling, and structural damage, helping maintain functional ability.
  • Crohn's disease: induces and maintains remission of intestinal inflammation in patients with moderate to severe disease who have not responded adequately to conventional therapy.

How It Works

  • Ustekinumab binds selectively to the p40 subunit shared by interleukin‑12 and interleukin‑23, preventing these cytokines from engaging their cell‑surface receptors. This inhibition blocks downstream signaling pathways that drive Th1 and Th17 cell activation, thereby reducing the production of pro‑inflammatory mediators and attenuating the pathological immune response characteristic of psoriasis, psoriatic arthritis, and Crohn's disease.

Side Effects

Adverse reactions may occur with ustekinumab therapy.

Common Side Effects

  • Injection site reactions: redness, swelling, or pain at the infusion site.
  • Upper respiratory tract infection: symptoms such as sore throat, nasal congestion, or cough.
  • Headache: mild to moderate intensity, often transient.
  • Fatigue: general feeling of tiredness without a clear cause.
  • Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects

  • Serious infections: including tuberculosis or opportunistic infections.
  • Malignancies: potential increased risk of certain cancers.
  • Severe hypersensitivity: anaphylaxis or severe allergic reactions.
  • Exacerbation of inflammatory bowel disease: worsening of Crohn's disease symptoms.
  • Demyelinating disorders: new or worsening neurological conditions.
  • Cardiovascular events: rare cases of myocardial infarction or stroke.

Precautions & Warnings

Before and during treatment, several safety considerations are recommended.

  • Screen for active infections: assess patients for bacterial, viral, or fungal infections prior to initiation.
  • Monitor for signs of infection: advise patients to report fever, chills, or unexplained illness promptly.
  • Assess tuberculosis risk: perform TB screening and treat latent infection before therapy.
  • Evaluate vaccination status: administer required inactivated vaccines before starting ustekinumab.
  • Avoid live vaccines during therapy: live attenuated vaccines are contraindicated while immunosuppressed.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ustekinumab may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Concurrent use with live vaccines: may cause vaccine‑derived infection.
  • Combination with other immunosuppressants: heightened risk of severe infections.
  • Known hypersensitivity to ustekinumab: can trigger life‑threatening allergic reactions.

Moderate Interactions (Monitor Closely)

  • Concomitant systemic corticosteroids: may amplify immunosuppressive effects.
  • Use of antibiotics for active infection: monitor therapeutic response and adjust as needed.
  • Non‑live vaccines: may have reduced efficacy; assess antibody response when appropriate.

Frequently Asked Questions

Imuldosa contains ustekinumab, which is prescribed for adults with moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease when other systemic therapies have not provided adequate control.

Ustekinumab targets the p40 subunit shared by interleukin‑12 and interleukin‑23, blocking their interaction with cell receptors. This inhibition reduces activation of Th1 and Th17 immune pathways, decreasing inflammatory cytokine production and mitigating disease activity.

The dosing regimen for Imuldosa is individualized. A qualified prescriber determines the appropriate dose, infusion schedule, and any subsequent maintenance dosing based on the patient’s specific condition and clinical response.

The safety of ustekinumab in pregnancy and lactation has not been fully established. Healthcare providers should weigh potential benefits against possible risks and discuss options with the patient before initiating therapy.

To place an order, submit an enquiry on the Imuldosa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Imuldosa (ustekinumab) targets both interleukin‑12 and interleukin‑23, whereas many alternatives focus on a single cytokine such as IL‑17 or TNF‑α. This broader inhibition can be advantageous for patients who have not responded to agents that block only one pathway, but individual response varies.

Imuldosa must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain product stability.

Imuldosa is supplied as a sterile solution for injection and is administered intravenously by a qualified healthcare professional. The initial dose is given as a weight‑based infusion, followed by maintenance doses at intervals determined by the prescriber.

Serious risks include the development of severe infections such as tuberculosis, potential malignancies, hypersensitivity reactions including anaphylaxis, and possible worsening of inflammatory bowel disease. Patients should be monitored closely for any signs of these conditions.

Imuldosa is contraindicated in individuals with known hypersensitivity to ustekinumab or any of its excipients, and in patients with active serious infections. Live vaccines should not be administered during treatment, and caution is advised for those with a history of malignancy or demyelinating disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ustekinumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT